AstraZeneca, Ardelyx to Collaborate on Novel NHE3-Inhibitor Drugs
AstraZeneca (AZ) has agreed to help shepherd Ardelyx’s NHE3-inhibitor program and primary Phase II compound to commercialization, promising to provide the California startup with as much as $272.5 million if new drugs are developed for certain bowel, kidney and renal disorders.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.